A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed
This article was originally published in PharmAsia News
Executive Summary
Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.